Mandatory notification of trade
The 44.000 shares were purchased at an average price of NOK 20,48 per share. Mr. Bernt-Olav Røttingsnes has a new holding in Navamedic after the purchase of 50.000 shares.
For further information, please contact:
Bernt-Olav Røttingsnes, CFO/IRO
E-mail: bor@navamedic.com
Office: +47 67 11 25 44
Mobile: +47 913 47 021
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world`s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. Navamedic`s product Glucomed®/Flexove(TM) has been approved across 25 EU/EEA states by European Medicines Agency (EMEA), as the first and only glucosamine based medicine against osteoarthritis. The company`s products will be sold through a network of sales, marketing and distribution partners. For more information, please see www.navamedic.com